BioTalk

Companies in the life sciences sector and its sub-sectors, including pharmaceuticals, medical devices, diagnostics and services, are...

This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...

On 24 September, the French National Agency for the Safety of Medicines and Health Products (ANSM) announced fines totalling €8 million...

This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...

On 18 July 2024 President Von der Leyen laid down the path for the next European Commission in her Political Guidelines for the next...

Earlier this summer, the Irish Pharmaceutical Healthcare Association (IPHA), which represents the international originator...

The UK life sciences industry takes centre-stage in two of the new Labour government’s “Five Missions For National Renewal”: economic...

In May 2024, the Dutch government published the draft bill for the new Cybersecurity Act (Cyberbeveiligingswet – “CSA”) for consultation...

On June 6, 2024, the Advocate General (AG) at the Court of Justice of the European Union (CJEU) delivered an opinion in case C-248/23...

On 8 April 2024, the Dutch Minister of Medical Care (the Minister) sent a letter to the Dutch House of Representatives (Kamerbrief)...

The latest edition of the Legal 500: Pharmaceutical Advertising Comparative Guide is now online. The aim of this guide is to provide its...

The World Health Organisation (WHO) has published regulatory considerations on artificial intelligence (AI) for healthcare in October...

Environmental awareness and the desire to limit or eliminate the impact of human activities on the environment have led to real political...

Bird & Bird’s international life sciences and healthcare team is at the forefront of the legal developments with regard to AI and the...

This article is part of a series that covers the proposed reforms to EU pharmaceutical legislation. To view our first article and the...

This article is part of a series that covers the proposed reforms to EU pharmaceutical legislation. To view our first article and the...